Highlights

  • Singular Health (ASX:SHG) closed flat at AUD 0.19 on 10 August 2026.
  • The company received a US$500,000 contracted licence payment from Provider Network Solutions during the June 2026 quarter.
  • 3DICOM MD was operating across 750 primary-care provider licences, with discussions underway regarding renewal and expansion.
  • Singular ended the June 2026 quarter with AUD 10.1 million in cash to support its US commercialisation strategy.

Singular Health (ASX:SHG) is progressing the commercialisation of its 3DICOM medical imaging software platform across the United States, with recent activity centred on enterprise deployments, healthcare pilots and potential network expansion.

The Perth-based health-technology company operates a software-focused model built around 3DICOM, which enables clinicians to securely access, share and interact with medical imaging data through three-dimensional visualisation tools.

Singular Health closed flat at AUD 0.19 on 10 August 2026. The company remains focused on converting existing healthcare relationships and pilot programs into broader recurring software Revenue .

FDA Clearance Supports 3DICOM Expansion

A key milestone for Singular Health was the US Food and Drug Administration 510(k) clearance received for 3DICOM MD Cloud in January 2026.

The clearance supports the company’s ability to commercialise its medical imaging platform within the US healthcare market.

3DICOM is designed to allow medical professionals to view conventional scans in interactive 3D formats and securely share imaging across healthcare networks.

For Singular Health (ASX:SHG), the regulatory clearance provides a foundation for enterprise deployments and further commercial discussions with healthcare organisations.

Provider Network Solutions Agreement Progresses

Singular reported continued progress with Provider Network Solutions (PNS), a Florida-based managed-services organisation serving approximately 3.7 million members.

During the June 2026 quarter, the company received a US$500,000 contracted licence payment from PNS under a Binding Enterprise Agreement dated 19 June 2025.

The agreement initially covered 1,000 3DICOM MD licences priced at US$800 per licence.

Singular reported that 3DICOM MD was operating across 750 primary-care provider licences and indicated that PNS had commenced discussions regarding renewal and potential expansion of licences due to expire at the end of the third quarter.

Additional US Healthcare Opportunities

Singular Health continues developing several additional commercial opportunities in the United States.

The company reported final-stage discussions with Puerto Rico health plan Triple-S and a Life Radiology pilot in Florida involving more than 230 enrolled patients.

It also outlined a 3DICOM EDU deployment with Miami-Dade County Public Schools, with the first cohort scheduled to commence in September 2026.

Another potential opportunity involves a statewide imaging repository in Florida, where a funding decision was expected during the third quarter.

These programs remain at different stages of development and will require further progress before contributing materially to recurring revenue.

Compliance Certifications Support Enterprise Engagement

Singular Health (ASX:SHG) has also developed a compliance framework designed to support engagement with larger healthcare organisations.

The company holds ISO 27001, HIPAA and SOC 2 Type II certifications, while HITRUST accreditation remains in progress.

Such certifications are relevant for healthcare software providers handling sensitive clinical information, particularly when working with enterprise clients and large provider networks.

The company’s ability to convert regulatory and compliance credentials into recurring customer contracts will remain an important part of its commercialisation strategy.

Cash Position Supports Expansion Activities

Singular ended the June 2026 quarter with AUD 10.1 million in cash.

The company indicated that this funding position provides close to two years of runway to support its US expansion plans.

The Balance Sheet was supported by an AUD 8 million Placement undertaken to fund the national rollout of 3DICOM, product development and Working Capital .

As the company remains in a pre-scale commercialisation phase, future financial performance will depend on the pace at which pilots and enterprise agreements convert into recurring licence revenue.

Outlook

Singular Health’s near-term priorities include progressing PNS licence renewal and expansion discussions, advancing the Life Radiology pilot, commencing the Miami-Dade County Public Schools deployment and pursuing additional US healthcare opportunities. The company also continues working towards HITRUST accreditation. Future progress will depend on commercial conversion, recurring licence growth and execution across its enterprise pipeline as Singular Health develops its position in the medical imaging software market.